A novel VSV-based vaccine platform for Zika virus

The Need: Addressing the Zika Virus Outbreak

The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus, there is currently no FDA-approved vaccine or antiviral drug available for Zika virus infection. The urgent need for an effective solution to prevent and mitigate the impact of Zika virus requires advanced technology and innovative approaches to vaccine development.

The Technology: Recombinant Vectors for Zika Virus Immunogenicity

The technology presented here offers a breakthrough solution to combat the Zika virus. It involves the use of recombinant vectors encoding Zika virus protein subunits, including the nonstructural protein 1 (NS1 protein), the envelope (E) protein, and the premembrane (prM) protein. These recombinant vectors, particularly using the vesicular stomatitis virus (VSV) vector as a backbone, can be engineered to contain attenuating mutations, making them suitable for safe and effective vaccine development.

Commercial Applications: Multiple Use Cases

The technology's versatility enables it to find applications in various commercial scenarios, including:

  • Zika Virus Vaccine Development: The recombinant vectors can be utilized as a foundation for developing safe and potent Zika virus vaccines, capable of inducing an effective immune response in vaccinated individuals.

  • Outbreak Control and Prevention: The technology provides a potential tool for controlling and preventing Zika virus outbreaks in regions with high disease prevalence.

  • Biomedical Research: The recombinant vectors can be utilized in biomedical research to gain insights into the Zika virus and its interactions with the human immune system, aiding in the development of new therapeutic approaches.

  • Pharmaceutical Industry: Pharmaceutical companies can employ this technology to develop and produce Zika virus vaccines for global distribution.

Benefits/Advantages: A Revolutionary Approach

The utilization of recombinant vectors for Zika virus vaccine development offers several compelling benefits and advantages:

  • Enhanced Immunogenicity: The technology's ability to encode essential Zika virus proteins, such as NS1, E, and prM, can stimulate a robust immune response in vaccinated subjects, leading to improved protection against Zika virus infection.

  • Safety and Attenuation: The incorporation of attenuating mutations in the VSV vector backbone ensures a safe vaccine candidate with reduced risk of adverse effects.

  • Versatility: The ability to utilize various viral vectors, including adenovirus, AAV, retrovirus, lentivirus, vaccinia virus, and others, allows for flexibility in vaccine development strategies.

  • Efficacy in Humans: The technology's potential to induce an effective immune response in humans, including pregnant individuals, is of paramount importance in curbing the Zika virus outbreak's devastating effects.

  • Accelerated Vaccine Development: The use of recombinant vectors expedites vaccine development and clinical testing, enabling a faster response to emerging Zika virus threats.

In conclusion, the technology of recombinant vectors encoding Zika virus protein subunits holds tremendous promise for combating the Zika virus outbreak and safeguarding global public health. Its capacity to induce a robust immune response, coupled with its safety and versatility, makes it an essential tool in the fight against Zika virus infection.


Patent # Title Country
1173934818877139.8 Recombinant Vectors Encoding Zika Virus Protein SubunitsRecombinant Vectors Encoding Zika Virus Protein Subunits United States of AmericaEurope

Loading icon